Zhengqiang Yang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Zhengqiang Yang has a total of 96 co-authors. Here are the top co-authors by number of shared publications:
Hai-Bin Shi
Department of Radiology, The First Affiliated Hospital, Nanjing Medical University, Nanjing, China
2 shared publicationsAiping Tian
Department of Traditional Chinese Medicine, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
1 shared publication- Aiping Zhou
Department of Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, China
1 shared publication Baocai Xing
Department of Hepatobiliary and Pancreatic Surgery Unit I, Beijing Cancer Hospital, Beijing, China
1 shared publicationCaoye Wang
Department of Interventional Radiology, First People's Hospital of Changzhou, Changzhou, Jiangsu 213000, P.R. China
1 shared publication- Chen Xu
Department of Intervention Radiology, Suzhou Municipal Hospital Affiliated to Nanjing Medical University, Suzhou, China
1 shared publication
Latest Publications
- 7 March 2025
- Published by Elsevier in Journal of Vascular and Interventional Radiology
- Vol. 36 (8) , 1341-1346
Comparison of the Effectiveness of Inguinal Lymphangiography and Transjugular Intrahepatic Portosystemic Shunt Creation in Cirrhosis-Related Chylous Ascites
- 7 March 2025
- Published by Elsevier in Journal of Vascular and Interventional Radiology
- Vol. 36 (8) , 1341-1346
Comparison of the Effectiveness of Inguinal Lymphangiography and Transjugular Intrahepatic Portosystemic Shunt Creation in Cirrhosis-Related Chylous Ascites
- Open Access
- 1 June 2024
- Published by KEAI Publishing in Bioactive Materials
- Vol. 36, 376-412
Nanomaterials modulate tumor-associated macrophages for the treatment of digestive system tumors
The treatment of digestive system tumors presents challenges, particularly in immunotherapy, owing to the advanced immune tolerance of the digestive system. Nanomaterials have emerged as a promising approach for addressing these challenges. They provide targeted drug delivery, enhanced permeability, high bioavailability, and low toxicity. Additionally, nanomaterials target immunosuppressive cells and reshape the tumor immune microenvironment (TIME). Among the various cells in the TIME, tumor-associated macrophages (TAMs) are the most abundant and play a crucial role in tumor progression. Therefore, investigating the modulation of TAMs by nanomaterials for the treatment of digestive system tumors is of great significance. Here, we present a comprehensive review of the utilization of nanomaterials to modulate TAMs for the treatment of gastric cancer, colorectal cancer, hepatocellular carcinoma, and pancreatic cancer. We also investigated the underlying mechanisms by which nanomaterials modulate TAMs to treat tumors in the digestive system. Furthermore, this review summarizes the role of macrophage-derived nanomaterials in the treatment of digestive system tumors. Overall, this research offers valuable insights into the development of nanomaterials tailored for the treatment of digestive system tumors.
- 1 June 2024
- Published by KEAI Publishing in Bioactive Materials
- Vol. 36, 376-412
Open AccessNanomaterials modulate tumor-associated macrophages for the treatment of digestive system tumors
The treatment of digestive system tumors presents challenges, particularly in immunotherapy, owing to the advanced immune tolerance of the digestive system. Nanomaterials have emerged as a promising approach for addressing these challenges. They provide targeted drug delivery, enhanced permeability, high bioavailability, and low toxicity. Additionally, nanomaterials target immunosuppressive cells and reshape the tumor immune microenvironment (TIME). Among the various cells in the TIME, tumor-associated macrophages (TAMs) are the most abundant and play a crucial role in tumor progression. Therefore, investigating the modulation of TAMs by nanomaterials for the treatment of digestive system tumors is of great significance. Here, we present a comprehensive review of the utilization of nanomaterials to modulate TAMs for the treatment of gastric cancer, colorectal cancer, hepatocellular carcinoma, and pancreatic cancer. We also investigated the underlying mechanisms by which nanomaterials modulate TAMs to treat tumors in the digestive system. Furthermore, this review summarizes the role of macrophage-derived nanomaterials in the treatment of digestive system tumors. Overall, this research offers valuable insights into the development of nanomaterials tailored for the treatment of digestive system tumors.
- Open Access
- 4 January 2022
- Published by S. Karger AG in Liver Cancer
- Vol. 11 (3) , 192-208
Systemic Therapy for Hepatocellular Carcinoma: Chinese Consensus-Based Interdisciplinary Expert Statements
Background: Hepatocellular carcinoma (HCC) is the most common type of liver cancer and causes many cancer-related deaths worldwide; in China, it is the second most prevalent cause of cancer deaths. Most patients are diagnosed clinically with advanced stage disease. Summary: For more than a decade, sorafenib, a small-molecular-weight tyrosine kinase inhibitor (SMW-TKI) was the only molecular targeted drug available with a survival benefit for the treatment of advanced HCC. With the development of novel TKIs and immune checkpoint inhibitors for advanced HCC, the management of patients has been greatly improved. However, though angiogenic-based targeted therapy remains the backbone for the systemic treatment of HCC, to date, no Chinese guidelines for novel molecular targeted therapies to treat advanced HCC have been established. Our interdisciplinary panel on the treatment of advanced HCC comprising hepatologists, hepatobiliary surgeons, oncologists, radiologists, pathologists, orthopedic surgeons, traditional Chinese medicine physicians, and interventional radiologists has reviewed the literature in order to develop updated treatment regimens. Key Messages: Panel consensus statements for the appropriate use of new molecular -targeted drugs including doses, combination therapies, adverse reaction management as well as efficacy evaluation, and predictions for treatment of advanced HCC with evidence levels based on published data are presented, thereby providing an overview of molecular targeted therapies for healthcare professionals.
- 4 January 2022
- Published by S. Karger AG in Liver Cancer
- Vol. 11 (3) , 192-208
Open AccessSystemic Therapy for Hepatocellular Carcinoma: Chinese Consensus-Based Interdisciplinary Expert Statements
Background: Hepatocellular carcinoma (HCC) is the most common type of liver cancer and causes many cancer-related deaths worldwide; in China, it is the second most prevalent cause of cancer deaths. Most patients are diagnosed clinically with advanced stage disease. Summary: For more than a decade, sorafenib, a small-molecular-weight tyrosine kinase inhibitor (SMW-TKI) was the only molecular targeted drug available with a survival benefit for the treatment of advanced HCC. With the development of novel TKIs and immune checkpoint inhibitors for advanced HCC, the management of patients has been greatly improved. However, though angiogenic-based targeted therapy remains the backbone for the systemic treatment of HCC, to date, no Chinese guidelines for novel molecular targeted therapies to treat advanced HCC have been established. Our interdisciplinary panel on the treatment of advanced HCC comprising hepatologists, hepatobiliary surgeons, oncologists, radiologists, pathologists, orthopedic surgeons, traditional Chinese medicine physicians, and interventional radiologists has reviewed the literature in order to develop updated treatment regimens. Key Messages: Panel consensus statements for the appropriate use of new molecular -targeted drugs including doses, combination therapies, adverse reaction management as well as efficacy evaluation, and predictions for treatment of advanced HCC with evidence levels based on published data are presented, thereby providing an overview of molecular targeted therapies for healthcare professionals.
- Open Access
- 30 April 2021
- Published by Society of Gastrointestinal Intervention in International Journal of Gastrointestinal Intervention
- Vol. 10 (2) , 72-76
Percutaneous radiologic gastrostomy in patients with amyotrophic lateral sclerosis: A safe and effective technique
Chen Xu, Zheng-Qiang Yang, Sheng Liu, Wei Yang, Hai-Bin Shi, and Wei-Zhong Zhou. Int J Gastrointest Interv 2021;10:72-6. https://doi.org/10.18528/ijgii210004
- 30 April 2021
- Published by Society of Gastrointestinal Intervention in International Journal of Gastrointestinal Intervention
- Vol. 10 (2) , 72-76
Open AccessPercutaneous radiologic gastrostomy in patients with amyotrophic lateral sclerosis: A safe and effective technique
Chen Xu, Zheng-Qiang Yang, Sheng Liu, Wei Yang, Hai-Bin Shi, and Wei-Zhong Zhou. Int J Gastrointest Interv 2021;10:72-6. https://doi.org/10.18528/ijgii210004
- Open Access
- 1 April 2021
- Published by Society of Gastrointestinal Intervention in International Journal of Gastrointestinal Intervention
- Vol. 10 (2) , 42-48
Percutaneous endoscopic gastrostomy
Percutaneous endoscopic gastrostomy (PEG) is a feasible and safe technique for patients who need long-term feeding and cannot eat orally. With the increasing maturity of PEG technique, a large number of patients receive PEG tube placement every year in the world. However, PEG tube placement is not necessary in some patients, and some other patients are not evaluated strictly, leading to serious complications. In a broad sense, the mainly two indications for PEG include long-term enteral nutrition and gastric decompression. On the other hand, the main contraindications of PEG are distal intestinal obstruction, severe coagulation abnormalities, and severe infection at the PEG site. In the first section of this review, the indications and contraindications of PEG are introduced. Although PEG tube placement is a relatively safe technique, it can still cause a number of complications, including minor and major complications. Through standard management and treatment, the outcome of most patients is very good. In the second section of this review, we describe a variety of minor and major tube-related complications, and the treatment and prevention of these complications. In addition, the preparation and post-insertion care are also very important for PEG, which can reduce the incidence of complications. In the last section of this review, we describe related issues about the preparation and post-insertion care of PEG. In conclusion, PEG tube placement is a widely accepted technique that can bring benefits to the right patients. Copyright (C) 2021, Society of Gastrointestinal Intervention.
- 1 April 2021
- Published by Society of Gastrointestinal Intervention in International Journal of Gastrointestinal Intervention
- Vol. 10 (2) , 42-48
Open AccessPercutaneous endoscopic gastrostomy
Percutaneous endoscopic gastrostomy (PEG) is a feasible and safe technique for patients who need long-term feeding and cannot eat orally. With the increasing maturity of PEG technique, a large number of patients receive PEG tube placement every year in the world. However, PEG tube placement is not necessary in some patients, and some other patients are not evaluated strictly, leading to serious complications. In a broad sense, the mainly two indications for PEG include long-term enteral nutrition and gastric decompression. On the other hand, the main contraindications of PEG are distal intestinal obstruction, severe coagulation abnormalities, and severe infection at the PEG site. In the first section of this review, the indications and contraindications of PEG are introduced. Although PEG tube placement is a relatively safe technique, it can still cause a number of complications, including minor and major complications. Through standard management and treatment, the outcome of most patients is very good. In the second section of this review, we describe a variety of minor and major tube-related complications, and the treatment and prevention of these complications. In addition, the preparation and post-insertion care are also very important for PEG, which can reduce the incidence of complications. In the last section of this review, we describe related issues about the preparation and post-insertion care of PEG. In conclusion, PEG tube placement is a widely accepted technique that can bring benefits to the right patients. Copyright (C) 2021, Society of Gastrointestinal Intervention.
- Open Access
- 31 October 2018
- Published by Society of Gastrointestinal Intervention in International Journal of Gastrointestinal Intervention
- Vol. 7 (3) , 172-175
Balloon dilation of epidermolysis bullosa-related esophageal strictures: A report of two cases
Wei-Zhong Zhou, Jing-Guo Xia, Zheng-Qiang Yang,* Chun-Gao Zhou, Lin-Bo Zhao, Sheng Liu, Hai-Bin Shi. Gastrointestinal Intervention 2018;7:172-5. https://doi.org/10.18528/gii170030
- 31 October 2018
- Published by Society of Gastrointestinal Intervention in International Journal of Gastrointestinal Intervention
- Vol. 7 (3) , 172-175
Open AccessBalloon dilation of epidermolysis bullosa-related esophageal strictures: A report of two cases
Wei-Zhong Zhou, Jing-Guo Xia, Zheng-Qiang Yang,* Chun-Gao Zhou, Lin-Bo Zhao, Sheng Liu, Hai-Bin Shi. Gastrointestinal Intervention 2018;7:172-5. https://doi.org/10.18528/gii170030
- Open Access
- 13 February 2018
- Published by Spandidos Publications in Molecular and Clinical Oncology
- Vol. 8 (4) , 600-602
Bronchobiliary fistula after multiple transcatheter arterial chemoembolizations for hepatocellular carcinoma: A case report
Bronchobiliary fistula (BBF) is a rare condition, defined as an abnormal communication between the bronchial system and the biliary tree. Patients with this condition usually present with massive biliptysis, and the mortality rate is high. BBF has been reported to occur in patients with congenital conditions, complications of trauma, hepatic abscesses and biliary tract obstruction (surgical as well as non‑surgical). However, to the best of our knowledge, BBF as a complication of transcatheter arterial chemoembolization (TACE) for hepatocellular carcinoma (HCC) has not been reported to date. We herein report a case of BBF developing as a complication following TACE in a 71‑year‑old male patient with HCC. The patient was treated by placement of a metallic biliary stent followed by percutaneous transhepatic biliary drainage to decompress the intrahepatic biliary tree, and his symptoms were immediately relieved.
- 13 February 2018
- Published by Spandidos Publications in Molecular and Clinical Oncology
- Vol. 8 (4) , 600-602
Open AccessBronchobiliary fistula after multiple transcatheter arterial chemoembolizations for hepatocellular carcinoma: A case report
Bronchobiliary fistula (BBF) is a rare condition, defined as an abnormal communication between the bronchial system and the biliary tree. Patients with this condition usually present with massive biliptysis, and the mortality rate is high. BBF has been reported to occur in patients with congenital conditions, complications of trauma, hepatic abscesses and biliary tract obstruction (surgical as well as non‑surgical). However, to the best of our knowledge, BBF as a complication of transcatheter arterial chemoembolization (TACE) for hepatocellular carcinoma (HCC) has not been reported to date. We herein report a case of BBF developing as a complication following TACE in a 71‑year‑old male patient with HCC. The patient was treated by placement of a metallic biliary stent followed by percutaneous transhepatic biliary drainage to decompress the intrahepatic biliary tree, and his symptoms were immediately relieved.
- 5 July 2017
- Published by Springer Nature in CardioVascular and Interventional Radiology
- Vol. 40 (11) , 1748-1755
Transarterial Chemoembolization Monotherapy Versus Combined Transarterial Chemoembolization–Microwave Ablation Therapy for Hepatocellular Carcinoma Tumors ≤5 cm: A Propensity Analysis at a Single Center
To compare effectiveness of transarterial chemoembolization (TACE) combined with microwave ablation (MWA; TACE–MWA) with TACE alone for treating hepatocellular carcinoma (HCC) tumors ≤5 cm.
- 5 July 2017
- Published by Springer Nature in CardioVascular and Interventional Radiology
- Vol. 40 (11) , 1748-1755
Transarterial Chemoembolization Monotherapy Versus Combined Transarterial Chemoembolization–Microwave Ablation Therapy for Hepatocellular Carcinoma Tumors ≤5 cm: A Propensity Analysis at a Single Center
To compare effectiveness of transarterial chemoembolization (TACE) combined with microwave ablation (MWA; TACE–MWA) with TACE alone for treating hepatocellular carcinoma (HCC) tumors ≤5 cm.